IRON241220P20000
- 0.00
- 0.000.00%
Disc Medicine Newsroom
Disc Medicine Is Maintained at Buy by Stifel
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $90
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $70 to $118
Express News | Disc Medicine Inc : Stifel Raises Target Price to $90 From $79
Disc Medicine (IRON) Gets a Buy From Wells Fargo
Promising Pipeline Developments Bolster Buy Rating for Disc Medicine
Disc Medicine Presents Data Showing Potential Benefits of 3 Investigational Drugs
Disc Medicine Highlights Clinical And Preclinical Data From BEACON And AURORA Trials Of Bitopertin And Phase 1 DISC-3405 Trial At ASH 2024, Showcasing Potential For Existing And New Indications While Advancing Pipeline Of Hematologic Disease Therapies
Scotiabank Remains a Buy on Disc Medicine (IRON)
Cantor Fitzgerald Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $99
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118
Douglas Tsao's Buy Rating for Disc Medicine: Promising Efficacy and Market Potential of DISC-0974 in Anemia Treatment
Promising Clinical Data and Strategic Advancements Drive Buy Rating for Disc Medicine
Reported Sunday, Disc Medicine Shares Phase 1b Results For DISC-0974 In Myelofibrosis Patients At ASH 2024, Starts Phase 2 Trial
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Express News | Disc Medicine Presents Positive Updated Results From Phase 1B Trial in Patients With Myelofibrosis (Mf) and Anemia in an Oral Presentation at the 66TH American Society of Hematology (Ash) Annual Meeting
Jefferies Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $111
Express News | Disc Medicine Inc: - To Issue and Sell up to $200 Million in Common Stock
Express News | Disc Medicine Inc: Entered Into a Controlled Equity Offering SM Sales Agreement With Cantor Fitzgerald & Co.